GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (OTCPK:AWHL) » Definitions » Return-on-Tangible-Asset

AWHL (Aspira Womens Health) Return-on-Tangible-Asset : -121.44% (As of Mar. 2025)


View and export this data going back to 2000. Start your Free Trial

What is Aspira Womens Health Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Aspira Womens Health's annualized Net Income for the quarter that ended in Mar. 2025 was $-7.41 Mil. Aspira Womens Health's average total tangible assets for the quarter that ended in Mar. 2025 was $6.10 Mil. Therefore, Aspira Womens Health's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -121.44%.

The historical rank and industry rank for Aspira Womens Health's Return-on-Tangible-Asset or its related term are showing as below:

AWHL' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -222.82   Med: -113.71   Max: -84.7
Current: -183.65

During the past 13 years, Aspira Womens Health's highest Return-on-Tangible-Asset was -84.70%. The lowest was -222.82%. And the median was -113.71%.

AWHL's Return-on-Tangible-Asset is ranked worse than
92.76% of 221 companies
in the Medical Diagnostics & Research industry
Industry Median: -4.07 vs AWHL: -183.65

Aspira Womens Health Return-on-Tangible-Asset Historical Data

The historical data trend for Aspira Womens Health's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Return-on-Tangible-Asset Chart

Aspira Womens Health Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -107.11 -104.35 -102.25 -141.23 -222.82

Aspira Womens Health Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -275.82 -253.84 -325.41 -108.33 -121.44

Competitive Comparison of Aspira Womens Health's Return-on-Tangible-Asset

For the Diagnostics & Research subindustry, Aspira Womens Health's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspira Womens Health's Return-on-Tangible-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Return-on-Tangible-Asset falls into.


;
;

Aspira Womens Health Return-on-Tangible-Asset Calculation

Aspira Womens Health's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-13.094/( (6.262+5.491)/ 2 )
=-13.094/5.8765
=-222.82 %

Aspira Womens Health's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-7.412/( (5.491+6.716)/ 2 )
=-7.412/6.1035
=-121.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Aspira Womens Health  (OTCPK:AWHL) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Aspira Womens Health Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspira Womens Health Business Description

Traded in Other Exchanges
N/A
Address
12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
Executives
Nicole Sandford director 12117 BEE CAVES RD BLDG 3, STE 100, AUSTIN TX 78738
Minh Hoang Merchant officer: General Counsel & Secretary 1210 AVONDALE ROAD, HILLSBOROUGH CA 94010
Torsten Hombeck officer: Chief Financial Officer 529 W 42ND ST #6V, NEW YORK NY 10036
Celeste Rachelle Fralick director 2801 MESA ROAD, LUBBOCK TX 79403
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Stefanie L. Cavanaugh director 1120 S CAPITAL OF TX HWY, BLDG 1, STE 300, AUSTIN TX 78746
Ellen O'connor Vos director C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Ryan Thinh Phan officer: CSO & COO 327 CARLTON AVE, LOS GATOS CA 95032
Jannie Prestridge Herchuk director 6331 LAVENDALE AVE, DALLAS TX 75230
Winfred Parnell director 6734 TALMADGE LANE, DALLAS TX 75230
Marlene Mclennan officer: Interim Chief Financial Office 400 SOUTH AUSTRALIAN AVENUE, SUITE 800, WEST PALM BEACH FL 33401
Ruby Sharma director 24 ARNOLD DRIVE, PRINCETON JCT. NJ 08550
Robert D Auerbach director C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Valerie Barber Palmieri director, officer: President and CEO 63 INDIAN LEDGE RD., MONROE CT 06468